The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service
This consensus provides a framework to support the effective introduction of novel treatments for MM in the NHS. The results were used to inform a checklist for use within haematology services when considering the provision of MM care specific to BCMA BsAbs.
Authors
- Kamaraj Karunanithi (ORCID: https://orcid.org/0000-0002-4708-8092)
- Tim Warren
- Gordon C Cook (ORCID: https://orcid.org/0000-0003-1717-0412)
- Inderjit Singh (ORCID: https://orcid.org/0000-0001-7834-1938)
- I.C. WALKER (ORCID: https://orcid.org/0000-0002-2548-4502)
- Karthik Ramasamy (ORCID: https://orcid.org/0000-0003-3385-3707)
- Sarah Henshaw
- Anish Tailor
- Norhayati Mohd Ali (ORCID: https://orcid.org/0000-0002-9739-0492)
- Rakesh Popat (ORCID: https://orcid.org/0000-0001-6553-4618)
- Supratik Basu (ORCID: https://orcid.org/0000-0003-2206-4796)
Institutions
- University of Wolverhampton (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Nottingham University Hospitals NHS Trust (GB)
- University College London Hospitals NHS Foundation Trust (GB)
- Pfizer (United Kingdom) (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- University Hospitals of North Midlands NHS Trust (GB)
- Queen Elizabeth Hospital (GB)
- Oxford University Hospitals NHS Trust (GB)
- The Royal Wolverhampton NHS Trust (GB)
- University College London (GB)
Publication Details
- Journal
- eJHaem
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1002/jha2.1038
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- National Institute for Health and Care Research
- University College London
- Pfizer UK